Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yohimbine for cognition in major depression
NCT02470026Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jun 2014
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of yohimbine in major depressive disorder (MDD) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Behavioral responses in two different conditions of noradrenergic stimulation at 2.5 hours and Physiological responses in two different conditions of noradrenergic stimulation at 2.5 hours. Started Jun 2014; status: completed.
02
Drugs
yohimbine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02470026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02470026.